Candida guilliermondii fungemia in patients with hematologic malignancies
- PMID: 16825364
- PMCID: PMC1489483
- DOI: 10.1128/JCM.00356-06
Candida guilliermondii fungemia in patients with hematologic malignancies
Abstract
The microbiological, clinical, and epidemiological features of most non-Candida albicans Candida species are well known, but much less is known about species such as Candida guilliermondii, an uncommon pathogen causing a variety of deep-seated infections in immunocompromised hosts. To characterize C. guilliermondii fungemia in patients with hematological malignancies and its susceptibility to antifungal drugs, all cases of C. guilliermondii fungemia diagnosed in our department between 1983 and 2005 were retrospectively analyzed and the literature was reviewed. C. guilliermondii caused 29/243 (11.7%) candidemia episodes diagnosed during the study period. Central venous catheters were the documented sources of candidemia in 19/29 episodes (65.5%), and invasive tissue infections were documented in 2 (6.9%). In the remaining eight, the catheter was not removed and the source of the fungemia remained obscure. Seven episodes ended in death, but only one could be attributed to invasive C. guilliermondii infection. Molecular typing data reveal no evidence of common infection sources. Isolates displayed high rates of in vitro susceptibility to amphotericin B (100%), voriconazole (95%), and fluconazole (90%) and lower rates of in vitro susceptibility to flucytosine (86%), itraconazole (76%), and caspofungin (33%). Our literature review confirms that C. guilliermondii is a significantly more frequent cause of candidemia among cancer patients compared with the general hospital population. It accounted for <1% of the total number of Candida bloodstream isolates reported in the articles we reviewed, with higher rates in Europe (1.4%) and Asia (1.8%) compared with North America (0.3%).
Figures


Similar articles
-
Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center.J Clin Microbiol. 2024 Nov 13;62(11):e0105724. doi: 10.1128/jcm.01057-24. Epub 2024 Oct 23. J Clin Microbiol. 2024. PMID: 39440933 Free PMC article.
-
Clinical features, antifungal susceptibility, and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-Taiwan.J Microbiol Immunol Infect. 2018 Aug;51(4):552-558. doi: 10.1016/j.jmii.2016.08.015. Epub 2017 May 17. J Microbiol Immunol Infect. 2018. PMID: 28625801
-
Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center.Antimicrob Agents Chemother. 2014 Aug;58(8):4565-72. doi: 10.1128/AAC.02670-14. Epub 2014 May 27. Antimicrob Agents Chemother. 2014. PMID: 24867979 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
[Clinical pathogenesis of candidemia caused by non-albicans Candida species].Nihon Ishinkin Gakkai Zasshi. 2009;50(4):225-8. doi: 10.3314/jjmm.50.225. Nihon Ishinkin Gakkai Zasshi. 2009. PMID: 19942793 Review. Japanese.
Cited by
-
Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance.Int J Mol Sci. 2012;13(1):774-787. doi: 10.3390/ijms13010774. Epub 2012 Jan 13. Int J Mol Sci. 2012. PMID: 22312285 Free PMC article.
-
Invasive Candida infections in patients with haematological malignancies and hematopoietic stem cell transplant recipients: current epidemiology and therapeutic options.Mediterr J Hematol Infect Dis. 2011;3(1):e2011013. doi: 10.4084/MJHID.2011.013. Epub 2011 Mar 15. Mediterr J Hematol Infect Dis. 2011. PMID: 21625317 Free PMC article.
-
Meyerozyma guilliermondii species complex: review of current epidemiology, antifungal resistance, and mechanisms.Braz J Microbiol. 2022 Dec;53(4):1761-1779. doi: 10.1007/s42770-022-00813-2. Epub 2022 Oct 28. Braz J Microbiol. 2022. PMID: 36306113 Free PMC article. Review.
-
In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.J Clin Microbiol. 2009 Oct;47(10):3170-7. doi: 10.1128/JCM.00942-09. Epub 2009 Aug 26. J Clin Microbiol. 2009. PMID: 19710283 Free PMC article.
-
Breakthrough candidemia with hematological disease: Results from a single-center retrospective study in Japan, 2009-2020.Med Mycol. 2023 Jun 5;61(6):myad056. doi: 10.1093/mmy/myad056. Med Mycol. 2023. PMID: 37312399 Free PMC article.
References
-
- Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128. - PubMed
-
- Chen, Y. C., S. C. Chang, K. T. Luh, and W. C. Hsieh. 2003. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother. 52:71-77. - PubMed
-
- Cheng, M. F., K. W. Yu, R. B. Tang, Y. H. Fan, Y. L. Yang, K. S. Hsieh, M. Ho, and H. J. Lo. 2004. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 48:33-37. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical